ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Enanta Pharmaceuticals to Participate in December Investor Conferences

November 19, 2021 GMT

WATERTOWN, Mass.--(BUSINESS WIRE)--Nov 19, 2021--

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two virtual investor conferences in December:

  • Evercore ISI 4 th Annual HealthCONx Conference, December 1, 2021 with a fireside chat at 10:30 a.m. ET.
  • Piper Sandler 33 rd Annual Healthcare Conference, December 2, 2021. Company pre-recorded fireside chat will become available to registered conference attendees on Monday, November 29, 2021 at 10:00 a.m. ET.

A webcast of the each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. Replays of the webcasts will be available following the presentations and will be archived for at least 14 days.

ADVERTISEMENT

About Enanta
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and SARS-CoV-2 (COVID-19). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com:https://www.businesswire.com/news/home/20211119005117/en/

ADVERTISEMENT

CONTACT: Investor

Jennifer Viera

617-744-3848

jviera@enanta.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: INFECTIOUS DISEASES BIOTECHNOLOGY HEALTH CLINICAL TRIALS

SOURCE: Enanta Pharmaceuticals, Inc.

Copyright Business Wire 2021.

PUB: 11/19/2021 07:00 AM/DISC: 11/19/2021 07:02 AM

http://www.businesswire.com/news/home/20211119005117/en